NCT07065552View on ClinicalTrials.gov

Tirzepatide in Obesity-Driven Endometrial Cancer

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Endometrial CancerObesity
Interventions
DRUG

Tirzepatide

Tirzepatide will be administered once weekly, subcutaneously, and patients will be taught how to administer this drug at home. Patients will be started on a dose of 5 mg tirzepatide weekly for four weeks prior to surgical staging. .

Trial Locations (1)

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT07065552 - Tirzepatide in Obesity-Driven Endometrial Cancer | Biotech Hunter | Biotech Hunter